Allergic asthma
Conditions
Interventions
Treatment group:Acupoint application + Budesonide and Formoterol powder inhaler
Control Group:Simulated Patch + Budesonide and Formoterol Powder Inhaler
Sponsors
Shanxi University of Traditional Chinese Medicine Affiliated Acupuncture and Massage Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnosis of mild to moderate chronic persistent allergic asthma; (2) Identified by TCM differential diagnosis as lung and spleen qi deficiency syndrome; (3) Age between 18 and 65 years; (4) No acupoint patch application within the past month; (5) Not participating in other clinical studies; (6) Able to cooperate with all required tests and measurements; (7) Voluntarily participates and signs the informed consent form. Subjects meeting all the above criteria will be included in the study.
Exclusion criteria
Exclusion criteria: (1) Patients in the acute exacerbation phase or clinical control phase of asthma; (2) Pregnant or breastfeeding women; (3) Individuals allergic to Western medicine (e.g., inhaled corticosteroids, etc.); (4) Patients allergic to the patch medication or adjuvants, or with keloid-prone constitution, or with skin trauma, ulcers, or infections at the patch site; (5) Patients with severe organic diseases of the heart, liver, kidneys, or blood system, a tendency to bleed, or other major illnesses; (6) Patients with concurrent infections or other respiratory diseases; (7) Patients with mental illness or cognitive dysfunction who are unable to cooperate with treatment or follow-up; (8) Patients who have participated in other clinical trials within the past 3 months. If any of the above applies, the individual cannot be included in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Asthma Control Test (ACT) Questionnaire; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM Syndrome Score;Adult Asthma Quality of Life Questionnaire Survey (AQLQ) Scoring;Acute exacerbations;Pulmonary function: First-second forced expiratory volume (FEV1), Forced vital capacity (FVC), Peak expiratory flow (PEF);Fractional Exhaled Nitric Oxide (FeNO); | — |
Countries
China
Contacts
Public ContactZhang Tiansheng
Shanxi Province Acupuncture Hospital
Outcome results
None listed